Varex Imaging Corp: directors' dealings · United States · SEC (Form 4)

About Varex Imaging Corp

Varex Imaging Corp. (Nasdaq: VREX) is a US-based specialized X-ray imaging technology company listed on the NASDAQ market in the United States. The company designs, manufactures, sells, and services critical components and subsystems used in medical imaging systems, as well as industrial and security inspection applications. Its core portfolio includes X-ray tubes, digital and photon-counting detectors, image-processing software, associated workstations, and other high-voltage and imaging-related components. In practical terms, Varex is a mission-critical supplier to OEMs that build imaging platforms for hospitals, security inspection, and industrial workflows. ([vareximaging.com](https://www.vareximaging.com/news/varex-announces-successful-completion-of-debt-refinancing/?utm_source=openai)) The company’s roots date back to the 1930s through Eimac Products and later the growth of Varian’s X-ray imaging franchise. Varex was then spun out as an independent company to house and expand the imaging components business. That heritage gives it a long operating track record and a deep technical base in imaging hardware and related software. Its global headquarters are in Salt Lake City, Utah, which places the company in a US innovation corridor with strong manufacturing and med-tech links. ([vareximaging.com](https://www.vareximaging.com/about-us/?utm_source=openai)) From a competitive standpoint, Varex occupies a strategically important niche. It is not primarily a systems vendor; instead, it supplies the core imaging building blocks that enable its customers to differentiate their own products. This makes Varex relevant across multiple end markets: medical imaging, non-intrusive cargo and vehicle screening, and selected industrial inspection uses. The model provides some diversification, but it also leaves the company exposed to customer capex cycles, technology adoption, and pricing pressure in component markets. ([vareximaging.com](https://www.vareximaging.com/news/varex-announces-successful-completion-of-debt-refinancing/?utm_source=openai)) Its product set spans CT tubes, flat-panel detectors, photon-counting detectors, image-processing software, 3D reconstruction tools, and cargo inspection systems. Recent company updates show a more active commercial and financial backdrop: Varex announced about $25 million of cargo inspection orders in May 2025, launched the XRD 3131N detector for high-throughput EV battery inspection, and completed a debt refinancing in March 2026 with total commitments of $490 million maturing in 2031. Management said the refinancing should improve financial flexibility and reduce annualized cash interest expense. These events highlight a business focused on both product execution and balance-sheet repair. ([vareximaging.com](https://www.vareximaging.com/news/varex-announces-non-intrusive-cargo-inspection-systems-orders-valued-at-25-million/?utm_source=openai)) For international investors, Varex is best viewed as a niche med-tech and industrial imaging infrastructure name rather than a broad healthcare company. Its exposure to CT replacement demand, security screening, and EV-related inspection trends can support long-term relevance, but the stock remains sensitive to OEM demand, macro cycles, and capital structure execution. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1681622/000168162225000106/exhibit991-q425earningsrel.htm?utm_source=openai))